Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
The goal for the project is the identification and optimization of anti-viral compounds.
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
The transaction is expected to close in the Q4FY22
Advances deployment of mRNA technology across vaccines and therapeutics development
CDSCO to fast-track trials and approval for COVID19 vaccine
Deal for 100 million doses with additional 100 million through 2023
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
It works as an adjunct to standard care based on robust clinical trials
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
